UBS Initiates Coverage On Harmony Biosciences with Buy Rating, Announces Price Target of $56
Portfolio Pulse from Benzinga Newsdesk
UBS has initiated coverage on Harmony Biosciences with a Buy rating and set a price target of $56.
September 10, 2024 | 12:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target by a major financial institution like UBS is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100